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The era of targeted therapy has introduced a new therapeutic perspective for melanoma patients. Treatment with
BRAFV600 inhibitors has improved overall and disease-free survival in metastatic melanoma patients whose
tumors harbor BRAFV600 mutations. Although the BRAFV600E mutation appears to have a critical role in tumor
initiation, its expression during tumor progression remains controversial. In fact, various authors claim that
BRAFV600E heterogeneity is evident in melanoma tumors. Herein, we investigated the pattern of BRAFV600E
expression in matched primary and metastatic samples from 140 patients. Using a combination of real-time PCR
and immunohistochemical analyses, we demonstrated that BRAFV600E expression is homogeneous in melanoma
tumors and hypothesized that the heterogeneity described by others might be attributable to technical issues
when molecular methods are used. We also demonstrated the high efﬁciency of the anti-BRAFV600E VE1 antibody
for the detection of BRAFV600E mutations in melanoma tumors.
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INTRODUCTION
The new era of targeted therapies has increased treatment
efﬁcacy with less overall toxicity in patients with cancer.
The v-raf murine sarcoma viral oncogene homolog B1 gene
(BRAF) is the target of somatic mutations in 40–60% of
melanoma patients (Goel et al., 2006; Ribas and Flaherty,
2011). The most common mutations detected in the BRAF
gene are BRAFV600E (~80%) and BRAFV600K (5–30% of the
cases; McArthur et al., 2014).
Emerging therapies that target the mutated BRAFV600
oncogene have improved overall and disease-free survival
rates in patients with advanced melanoma that harbor
BRAFV600E and BRAFV600K mutations (Chapman et al., 2011,
Kudchadkar et al., 2012, McArthur et al., 2014). In fact, the
use of selective BRAFV600 inhibitors in patients with metastatic
melanoma leads to high response rates with a relative reduc-
tion in the risk of death and disease progression compared
with dacarbazine (Chapman et al., 2011, McArthur et al.,
2014). Regardless of this initial response to BRAFV600
inhibitors, most patients relapse in clinical practice. Indeed,
complete response rates are rarely obtained, and many
patients are refractory to this treatment (Chapman et al.,
2011, Sosman et al., 2012).
Although the BRAFV600E mutation appears to have a critical
role in tumor initiation, consistent BRAFV600E expression
during melanoma progression is controversial, and recent
studies have demonstrated the presence of BRAFV600E
heterogeneity in melanoma tumors (Colombino et al., 2012;
Yancovitz et al., 2012; Heinzerling et al., 2013; Saint-Jean
et al., 2014). The presence of inter-tumoral (differences
between primary and metastatic tumors) or intra-tumoral
(differences among different subclones within the tumor)
heterogeneity of the BRAFV600E mutation in melanoma might
be an intrinsic mechanism of resistance to BRAFV600
inhibitors. Furthermore, tumor heterogeneity might lead to
diagnostic problems in clinical practice (e.g., sample selec-
tion and BRAFV600 mutation detection using a primary or
a metastatic melanoma specimen).
Different molecular methods are available to detect
BRAFV600 mutations (Curry et al., 2012). For instance, the
cobas 4800 BRAFV600 Mutation Test (Roche Diagnostics,
Mannheim, Germany) has been used for patient management
in most countries. Recently, a monoclonal antibody against
BRAFV600E has been developed to detect this mutated protein
in tumor parafﬁn sections (Capper et al., 2011). Studies of
melanoma tumors that harbor the BRAFV600E mutation
revealed high antibody sensitivity and speciﬁcity (Capper
et al., 2012; Skorokhod et al., 2012; Colomba et al., 2013).
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Given that immunohistochemistry (IHC) is a routine tech-
nique used by most hospitals worldwide, the anti-BRAFV600E
antibody could serve as an efﬁcient tool to identify BRAFV600E
mutations in melanoma tumors.
Herein, we investigated the BRAFV600E mutation pattern in
paired primary and metastatic melanomas from 140 patients
using the molecular cobas method combined with IHC
analysis. The main goal of this study was to determine
whether BRAFV600E heterogeneity exists in melanoma patients
and to study the efﬁciency of IHC for detecting this mutation
in melanoma samples.
RESULTS
Patients and melanoma specimens
A total of 140 patients with advanced melanoma (AJCC stage
III or IV) from three reference hospitals in Spain were enrolled
in this study. The cases were selected according to the
availability of primary and metastatic specimens from the
same patient. In total, 140 primary melanomas and 171
metastases were examined.
The clinical and histological data are summarized in
Supplementary Table S1 online. Most of the patients were
male (51.4%). The patient age at diagnosis ranged from 17 to
87 years (median 58.9). The trunk was the most common
location of primary melanoma (35.7%). Regarding the
histological features of primary tumors, superﬁcial spreading
melanoma was the most frequent type of melanoma (55%).
The median Breslow thickness was 4.18 mm (range 0.4 to
35mm), and ulceration was identiﬁed in 53.6% of tumors. No
or low numbers of inﬂammatory cells were detected in 77.2%
of melanomas. The metastatic lesions analyzed included skin/
subcutaneous (n= 62), lymph node (n= 100), and visceral
(n=9) metastases.
A study of paired melanoma samples with the cobas test
revealed the inter-tumoral heterogeneity of BRAFV600 mutations
We investigated the BRAFV600 mutational status in paired
primary and metastatic melanoma samples from 140 patients.
A total of 311 tumors, including 140 primary and 171
metastatic melanomas, were analyzed for BRAFV600 muta-
tions using the real-time PCR (qPCR) cobas 4800 BRAFV600
Mutation Test. In all, 110 patients each had a single metastatic
lesion, 29 patients had 2 metastases, and 1 patient had 3
metastases examined. All of the samples were macrodissected
for DNA extraction and BRAFV600 analysis with the cobas test.
The BRAFV600 mutation was detected in 52.9% (74/140) of
primary melanomas and in 52.0% (89/171) of metastatic
specimens (Supplementary Table S2 online).
After a comparison of the BRAFV600 mutation pattern
between paired primary and metastatic samples, 117 patients
(83.6%) presented a consistent mutational pattern, whereas
23 patients (16.4%) exhibited a discordant mutational pattern.
Interestingly, the three reference hospitals that were enrolled
in this study reported a similar percentage of discrepant cases.
The ﬁrst hospital analyzed 62 patients and identiﬁed 10
discrepant cases (16.1%). The second hospital analyzed 49
patients and identiﬁed 8 discordant cases (16.3%), and the
third hospital analyzed 29 patients and identiﬁed 5 discordant
cases (17.2%). Among the 30 patients with multiple meta-
static samples, 5 patients (16.7%) exhibited a discordant
Table 1. Analysis of the BRAFV600 mutation pattern
between paired melanoma samples using the cobas
test
Total cases
Concordant Discordant Cases examined
n (%) n (%) n
Hospital 1 52 (83.9%) 10 (16.1%) 62
Hospital 2 41 (83.7%) 8 (16.3%) 49
Hospital 3 24 (82.8%) 5 (17.2%) 29
Total 117 (83.6%) 23 (16.4%) 140
Patients studied
n=140
Concordant status
n=117
Concordant status
n=61
Concordant status
n=22
qPCR
IHC IHC
Not analyzed
n=56
2 primary
melanomas
Discordant status
n=23
Discordant status
n=0
Discordant status
n=1
Figure 1. Study ﬂow of the melanoma samples enrolled in this study. Samples were analyzed for the presence of BRAFV600E mutations by cobas real-time PCR
(qPCR) and immunohistochemistry (IHC).
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BRAFV600 mutational pattern (Table 1, Supplementary Table
S3 online and Figure 1).
From the 23 discordant cases identiﬁed by the cobas test,
12 patients presented BRAFV600 mutations in primary
melanomas with wild-type metastases, and 11 patients
exhibited wild-type primary melanomas with BRAFV600-
mutated metastases.
Immunohistochemical analysis revealed a consistent expression
of the BRAFV600E mutation in the initially discordant cases
Given the controversy of inter-tumoral BRAFV600E patterns,
we also analyzed the paired samples with IHC using a highly
sensitive and speciﬁc antibody against the BRAFV600E mutant
protein.
Regarding the 117 concordant cases determined by the
cobas test, we were able to complement the study of 61
matched primary and metastatic samples with anti-BRAFV600E
staining. Of the 61 patients, 46 had 1 metastatic specimen that
was analyzed, and 15 patients had 2 metastases that were
analyzed by IHC. As expected, all of the cases exhibited a
consistent expression pattern of the BRAFV600E mutation
according to IHC analysis (Figure 1).
Regarding the 23 patients with discordant mutational
pattern identiﬁed by the cobas test, 18 patients had the
primary and 1 metastatic tumors analyzed, and 5 patients had
the primary and 2 metastatic tumors analyzed by IHC.
Surprisingly, the immunohistochemical study of the 23
discordant cases revealed consistent BRAFV600E mutational
patterns in 22 patients (Table 2 and Figure 2). Only 1 patient
(case ♯13) maintained the discordant mutational pattern after
IHC analysis. After a revision of the clinical history of this
patient, we determined that he had two primary melanomas
that were diagnosed simultaneously and that the thinner
primary melanoma (1.55 mm Breslow thickness) was used for
the cobas analysis. We then submitted the second melanoma
(7.10mm Breslow thickness) for IHC and Sanger sequencing
analyses and observed that it harbored the BRAFV600E
mutation, which suggests that this case also presented with
a consistent BRAFV600E mutational pattern (Table 2).
In addition, we used the Sanger method to sequence
exon 15 of the BRAF gene in the melanoma samples of
the 23 discrepant cases. The IHC results were conﬁrmed
by Sanger sequencing in all of the cases, with the excep-
tion of three metastases that were wild type by Sanger
sequencing but positive by IHC. Five cases that were negative
by IHC were proven to harbor the BRAFV600K mutation
(Table 2).
A review of all of the samples from the inconsistent cases
revealed that 11 cases (♯1, ♯2, ♯6, ♯7, ♯8, ♯9, ♯10, ♯11, ♯15,
♯16, and ♯21) presented a small number of tumor cells in the
tested sample (o25% tumor content before macrodissection).
Five cases (♯5, ♯12, ♯17, ♯18, and ♯20) presented the V600K
mutation, and 1 case (♯13) had two primary melanomas. Two
cases (♯22 and ♯23) presented metastases that were mutated
according to the cobas test but that were wild type according
to IHC and sequencing. We repeated the cobas test using the
same genomic DNA from these samples that had been used
for sequencing, and the second analysis conﬁrmed the wild-
type status. We were unable to ﬁnd an explanation for the
discrepancy observed in 4 cases (♯3, ♯4, ♯14, and ♯19). After
the additional molecular analyses by Sanger sequencing and
the cobas test, 3 of the 23 cases remained discordant (Table 2).
In summary, the use of IHC revealed inter-tumoral
homogeneous expression of the BRAFV600E mutation in
100% of the paired samples studied (n=84, including 1 case
with 2 primary melanomas). Moreover, the initially discordant
cases originally obtained by the cobas test were consistent by
IHC analyses.
Immunohistochemical analysis demonstrated intra-tumoral
homogeneity of BRAFV600E mutations in melanoma specimens
In addition, to clarify whether intra-tumoral heterogeneity of
BRAFV600E expression in melanomas occurs, we evaluated a
total of 239 specimens that were stained with an anti-
BRAFV600E antibody. The examined specimens included 127
primary melanomas and 112 metastases. Of the 239
melanomas, 137 melanomas (72 primary and 65 metastatic
lesions) were positive for anti-BRAFV600E staining. All of these
samples demonstrated homogeneous BRAFV600E expression
throughout the tumor area (Figure 3). None of the specimens
presented both positive and negative subclones within the
tumor. Differences in the staining pattern were observed in
few tumors (o2%) and were attributed to staining artifacts
caused by air bubbles under the section and necrotic tumor
regions (Supplementary Figure S1 online).
IHC demonstrated high efﬁciency for the detection of
BRAFV600E mutations in melanoma tumors
We also compared the cobas 4800 BRAFV600 Mutation Test
with IHC detection of the BRAFV600E mutation in our series of
melanoma samples. Of the 239 tumors examined, 208 tumors
exhibited results similar to those obtained with the cobas
4800 BRAFV600 Mutation Test, whereas IHC revealed 31
tumors with inconsistent results. A total of, 112 samples
harbored the BRAFV600E mutation according to both the cobas
test and the IHC, 96 samples were wild type according to both
techniques, 25 were mutated based on IHC but wild type
according to cobas, and 6 were wild type based on IHC but
mutated according to cobas (Table 3). The percentage of
samples that were consistent was 87.03% (95% conﬁdence
interval 82.56–91.50), and the Kappa value was 0.7411 (95%
conﬁdence interval 0.6571–0.8250). These results indicate a
good level of agreement between the two techniques.
The discrepant tumors were also analyzed by Sanger
sequencing to conﬁrm the presence of BRAF mutations.
Supplementary Table S4 online, depicts the inconsistent
samples with the results of the three techniques and the
percentage of tumor cell content of each sample. From the 25
tumors that were determined to be wild-type by cobas but
mutated by IHC, sequencing conﬁrmed the presence of the
BRAFV600E mutation in 16 of the tumors, whereas 6 samples
were classiﬁed as wild type according to sequencing analysis,
and 3 tumors could not be sequenced. All of the samples
(n=6) that were wild type based on IHC but mutated
according to cobas were shown to harbor a V600K mutation
by sequencing analysis.
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DISCUSSION
The emergence of resistance to BRAFV600 inhibitors has
rapidly become a “hot topic” in melanoma research. The
existence of intra- or inter-tumoral heterogeneity of the
BRAFV600 mutation could serve as a primary mechanism of
resistance. Despite the initial belief that the BRAFV600E
mutation is consistently expressed during melanoma progres-
sion, some investigators advocate for the existence of
BRAFV600E heterogeneity in melanoma tumors (Colombino
et al., 2012; Yancovitz et al., 2012; Heinzerling et al., 2013;
Saint-Jean et al., 2014).
Various molecular methods have long been used for the
detection of BRAF mutations in human tumors; however, the
efﬁcacy of such techniques depends on the percentage of
tumor cells in the specimen used for the analysis (Lade-Keller
et al., 2013). Such methods require thorough techniques for
tumor dissection and DNA extraction, and the selection of
specimens with abundant inﬂammatory and stromal cells or
errors in tumor processing could be responsible for the low
sensitivity and speciﬁcity of these methods.
In our study, we addressed this issue using a combination of
qPCR and IHC analysis. We investigated paired melanoma
samples with the cobas test, which is the most commonly
used method for patient management. We subsequently
performed IHC with VE1, a new monoclonal BRAFV600E
mutation–speciﬁc antibody.
In total, 140 cases from three reference hospitals were
analyzed using the cobas test. Comparing the BRAFV600 status
between the primary and metastatic samples revealed an
inter-tumoral heterogeneity of 16.4% in our case series.
All three hospitals demonstrated similar rates of discordance
(16.1, 16.3, and 17.2%).
Interestingly, our IHC study of the discordant cases
obtained by the cobas test revealed a consistent pattern of
BRAFV600E expression in the paired samples. Only one case
was discordant after IHC analysis. This patient was diagnosed
with two primary melanomas simultaneously; one lesion was
Primary
WTqPCR
IHC
SEC
V600
V600E V600E V600K V600K V600E
WT
WT
V600 WTV600
PrimaryMetastasis Metastasis Primary Metastasis
Figure 2. Illustrative cases of paired melanoma samples analyzed by cobas real-time PCR (qPCR), immunohistochemistry (IHC), and Sanger sequencing (SEC).
Paired samples of primary and metastatic melanoma exhibited a discordant pattern of BRAF mutations by qPCR analysis. IHC of the paired samples revealed a
consistent pattern of BRAFV600E expression. Sequencing of the samples conﬁrmed the consistent pattern of BRAF mutations (left and middle); however,
sequencing failed to detect BRAF mutations in samples with a low percentage of tumor cells (right). Bar= 500 μm (upper) and 100 μm (below).
Figure 3. Representative images of anti-BRAFV600E staining. Immunostaining
of primary (left) and metastatic (right) samples revealed homogeneous
distribution of BRAFV600E expression in melanoma tumors. Bar=200 μm.
Table 3. Results obtained from comparing the cobas
4800 BRAFV600 Mutation Test and IHC with an
anti-BRAFV600E-speciﬁc antibody for the detection of
BRAF mutations in melanoma samples
Results Number of samples
qPCR mutated/IHC mutated 112
qPCR WT/IHC WT 96
qPCR mutated/IHC WT 6
qPCR WT/IHC mutated 25
Total 239
Abbreviations: IHC, immunohistochemistry; qPCR, real-time PCR Cobas
test; WT, wild type.
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wild type, and the other contained the BRAFV600E mutation.
We believe that the primary melanoma that gave rise to the
mutated metastatic tumor was in fact the mutated primary
tumor, which had a greater Breslow thickness (7.1 mm)
compared with the wild-type primary melanoma (1.55 mm).
In total, we analyzed 84 matched primary and metastatic
samples by IHC, conﬁrming the consistent expression of
BRAFV600E.
Similar rates of discordance have been described by other
groups using different molecular methods (range 13.5 to
44%). With the mutant-speciﬁc PCR method, Yancovitz et al.
(2012) reported a 44% rate of discordance for the BRAFV600E
mutation status when comparing paired primary and
metastatic samples from 18 patients. Colombino et al.
(2012) sequenced paired melanoma samples from 99
patients and reported a 15% discrepancy rate in the BRAF
and/or NRAS mutation patterns between primary and
metastatic tumors. Heinzerling et al. (2013), sequenced
multiple tumor samples from 53 patients and reported a
BRAF heterogeneity status in 18.9% of patients. More
recently, Saint-Jean et al. (2014) analyzed several melanoma
samples from 74 patients using allele-speciﬁc ampliﬁcation
and Sanger sequencing and observed a 13.5% discordance
rate between paired samples.
In contrast, few authors have identiﬁed the existence of
inter-tumoral BRAFV600E mutation homogeneity in melanoma
tumors. Boursault et al. (2013) analyzed 88 paired melanoma
samples by IHC and high-resolution melting analysis followed
by Sanger sequencing and identiﬁed only four discrepant
cases. Interestingly, one patient had two primary melanomas,
and, two cases had very rare BRAF mutations (BRAFL597S
and BRAFD594N), suggesting that these mutations might have
been acquired during melanoma progression. Recently,
Menzies et al. (2014) studied paired samples of 64 patients
by IHC and identiﬁed an inter-tumoral concordance rate
of 100%.
We hypothesize that contamination with keratinocytes,
inﬂammatory or stromal cells, as well as errors during
macrodissection might decrease the sensitivity of certain
molecular methods in samples with a low percentage of
tumor cells, which could account for most of the discordant
cases identiﬁed in this study. However, we were unable to
explain the low efﬁcacy of the cobas test in four of the
discordant cases that had a high percentage of tumor cells. In
addition, two cases presented false-positive results in the ﬁrst
cobas analysis.
Technical issues have already been reported as a cause of
BRAFV600E heterogeneity. Twenty of the cases reported by
Yancovitz et al. (2012) presented discordance between
the two initial mutant-speciﬁc PCR reactions. Heinzerling
et al. (2013) also referred to one case with different BRAF
results based on the assay used (pyrosequencing or capillary
sequencing). Saint-Jean et al. (2014) identiﬁed multiple
BRAF tests detected BRAF mutations in ﬁve cases that were
previously determined to be wild type. Altogether, these
technical issues might explain the inconsistent results
between primary and metastatic melanomas when different
molecular tests are used for BRAF detection.
The decreased sensitivity of the cobas test for the
identiﬁcation of the V600K mutation might also result in a
higher expected rate of discordance when this method is
used. V600K mutations are detected in 67% of the specimens
by cobas (Halait et al., 2012), even if they are negative by IHC
(Colomba et al., 2013; Long et al., 2013). In fact, in our study,
we observed a high incidence of V600K mutation (21.7%)
among the initially discordant cases.
We also observed homogeneous expression of the
BRAFV600E protein throughout the tumor area in our series
of melanomas, which supports the BRAFV600E intra-tumoral
homogeneity described by previous reports (Capper et al.,
2011, 2012; Boursault et al., 2013; Long et al., 2013;
Kakavand et al., 2014).
Most of the studies that claim the existence of intra-tumoral
heterogeneity have used molecular techniques for BRAFV600E
detection (Lin et al., 2011; Yancovitz et al., 2012; Chiappetta
et al., 2014). Interestingly, Yeh et al. (2013) recently explored
the impact of stromal cells in false-negative results obtained
by molecular methods. In an analysis of the frequency of
BRAFV600E-mutated cells within acquired nevi by droplet
digital PCR, the authors initially identiﬁed BRAFV600E muta-
tion heterogeneity. However, when the analysis was adjusted
for the degree of stromal contamination, the lesions proved to
be fully clonal for the BRAFV600E mutation. On the other hand,
Busam et al. (2013) observed the presence of BRAFV600E-
immunopositive and BRAFV600E-immunonegative cell
populations in 2 of the 20 primary melanomas and 6 of the
44 metastatic tumors analyzed by IHC.
Additional clinical and in vitro data corroborate the
concept of BRAFV600E homogeneity in melanoma tumors.
The lesions from individual patients treated with BRAFV600
inhibitors exhibit a homogeneous response when imaged with
[(18)F]ﬂuorodeoxyglucose-positron emission tomography
(MacArthur et al., 2012). Moreover, melanoma cells that
are resistant to BRAFV600 inhibitors retain expression of the
BRAFV600E mutation (Poulikakos et al., 2011).
We also sought to assess the efﬁciency of IHC for the
detection of the BRAFV600E mutation in melanoma samples
and observed a good level of agreement with the cobas test. In
fact, IHC was able to detect more specimens harboring
BRAFV600E mutations compared with the cobas test. The high
efﬁciency of IHC described in our study is consistent with
other groups that previously reported the high sensitivity and
speciﬁcity of the anti-BRAFV600E VE1 antibody (Marin et al.,
2014; Skorokhod et al., 2012; Colomba et al., 2013; Chen
et al., 2014).
Another concern of note is the increased rate of BRAF
mutation detected by Sanger sequencing compared with the
cobas test (Qu et al., 2013). In our study, 16 tumors identiﬁed
as wild type by cobas contained the V600E mutation by
Sanger sequencing.
In conclusion, we present the largest series of paired
primary and metastatic melanomas that have been analyzed
for BRAFV600 mutation to date. By using sequential
IHC analysis of cases found to be discordant by qPCR, we
demonstrated consistent BRAFV600E mutation status in paired
melanoma samples. Although melanoma is an extremely
E Riveiro-Falkenbach et al.
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heterogeneous tumor type with considerable variation regard-
ing the clinical, histological, and genetic aspects, the homo-
geneous staining pattern of BRAFV600E mutation observed in
our study suggests that the status of BRAF is consistent during
melanoma progression and that BRAFV600E heterogeneity is
an improbable mechanism of intrinsic resistance to BRAFV600
inhibitors. Despite the absence of BRAF heterogeneity in our
study, we propose that metastatic samples should be used for
BRAF detection, given that patients can present with two or
more primary melanomas of different BRAF status. Finally, our
data support IHC as an efﬁcient tool for the detection of
BRAFV600E mutation in melanoma tumors, although molecu-
lar analysis remains necessary to detect the V600K mutation
in tumors that stain negative by IHC because patients with the
BRAFV600K mutation would beneﬁt from treatment. Further
studies that assess the reproducibility of the anti-BRAFV600E
VE1 antibody between different laboratories would be of great
interest to evaluate the clinical applicability of IHC.
MATERIALS AND METHODS
Melanoma samples
Melanoma samples from 140 patients were included in this study.
Cases were selected according to the availability of primary and
metastatic specimens from the same patient. A total of 311 tumors
including 140 primary and 171 metastatic melanomas were
analyzed. Metastatic tumors included skin/subcutaneous (n= 62),
lymph node (n= 100), and visceral (n= 9) metastases. Hematoxylin
and eosin slides from all the tumors were examined to conﬁrm the
presence of tumor cells. The study was approved by the institutional
review board of Hospital 12 de Octubre and is in accordance with
the Declaration of Helsinki Principles. Written informed consent
was obtained in accordance with the Spanish Law 14/2007 on
Biomedical Research.
Detection of BRAFV600 mutation using the cobas 4800 BRAFV600
Mutation Test
Melanoma tumors were analyzed for BRAFV600 mutations using the
cobas 4800 BRAFV600 Mutation Test. Cobas is a molecular method
based on genomic DNA extraction and target ampliﬁcation by qPCR.
Sixty-two, 49, and 29 cases were independently analyzed in each of
the three reference hospitals in Spain. All of the specimens were
macrodissected for DNA extraction and were analyzed using a
standard protocol (Halait et al., 2012). The results were scored as
“mutated” or “wild type” with respect to BRAFV600 status.
IHC
IHC was performed on 4 μm-thick sections of formalin-ﬁxed,
parafﬁn-embedded tissue samples using an anti-BRAFV600E mouse
monoclonal primary antibody (clone VE1). Immunostaining was
performed on a Ventana BenchMark GX stainer (Ventana Medical
Systems, Roche Group, Tucson, AZ) with pre-diluted Ventana
anti-BRAFV600E (VE1) mouse monoclonal primary antibody and the
Ventana Optiview DAB IHC detection kit according to the
manufacturer’s instructions (Ventana Medical Systems). Immunos-
taining was also performed on a Leica Bond-III stainer (Leica
Biosystem, Newcastle, UK) with a 1:100 dilution of anti-BRAFV600E
(VE1) mouse monoclonal primary antibody (Spring Bioscience,
Pleasanton, CA) and the Leica Bond Polymer Reﬁne Kit (Leica
Biosystem). The staining results were independently analyzed by two
pathologists and were blindly evaluated with respect to BRAFV600E
mutational status. The slides were scored as positive for strong
or weak staining intensity, negative in the absence of staining, or
NA (not available) to indicate insufﬁcient material for analysis.
Sanger sequencing
A total of 50–100 ng of genomic DNA from parafﬁn-embedded
macrodissected tissue was used. PCR ampliﬁcation of exon 15 of
the BRAF gene was performed using previously described PCR
conditions (Lovly et al., 2012). BRAF mutation screening was
performed by Sanger sequencing on a 3130× L Genetic Analyzer
(Life Technologies-Applied Biosystems, Foster City, CA).
Statistical analysis
The percentage of agreement and reliability estimates (kappa statistic)
for the detection of BRAF mutation in melanoma samples between the
cobas 4800 BRAFV600 Mutation Test and IHC with an anti-BRAFV600E
antibody are presented with 95% conﬁdence intervals (Kottner et al.,
2011). According to Landis and Koch (1977), the following kappa
values were used: poor to fair (o0.40), moderate (0.41–0.60), good
(0.61–0.80), and very good (0.81–1.0; Landis and Koch, 1977).
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